A Phase 4 interventional study of Sugammadex and Neostigmine and glycopyrrolate in Anaesthesia, sponsored by Tampere University Hospital. Completed at 1 site in Finland. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-06-11.
Sponsored by Tampere University Hospital · Phase 4, Interventional, and Treatment
According to our experience, electroencephalogram-based indices of anaesthetic state show elevated numbers after administration of sugammadex (new reversal of neuromuscular blockade). This can be due to altered anaesthetic state, or some kind of artefact. In this study, the phenomenon is evaluated in detail.
Rocuronium-induced neuromuscular blockade is antagonized with sugammadex or neostigmine. BIS, Entropy and the biosignal collected from the Entropy strip are collected on computer. The behaviour of these parameters before, during and after reversal on neuromuscular blockade will be analyzed in detail.
Tampere University Hospital is the lead sponsor of 209 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Sugammadex 200 mg iv, single dose, bolus.
Also known as: Bridion
Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
Also known as: Glycostigmin.
The behaviour of depth of anaesthesia indexes (BIS,SE,RE)
Time frame: 30 minutes
The behaviour of electroencephalography
Time frame: 30 minutes
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tampere University Hospital